Search for a trial

A randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of remibrutinib versus teriflunomide in participants with relapsing multiple sclerosis, followed by extended treatment with open-label remibrutinib.

This study has been transitioned to CTIS with ID 2023-509345-12-00 check the CTIS register for the current data. The purpose of the study is to provide efficacy, safety and tolerability data for remibrutinib to support regulatory approval worldwide…